Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status approved
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII 3XC8GUZ6CB
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Death08.04.01.001--
Dementia17.03.01.001; 19.20.02.0010.000455%-
Depression19.15.01.001--
Dermatitis23.03.04.0020.000667%-
Dermatitis allergic10.01.03.014; 23.03.04.0030.000667%-
Dermatitis bullous23.03.01.0020.000455%
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.000303%
Dermatomyositis10.04.04.027; 15.05.01.002; 23.03.02.0010.000303%-
Developmental delay08.01.03.037; 19.07.05.0030.000303%-
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.0040.000758%-
Diffuse large B-cell lymphoma01.15.02.001; 16.28.02.0010.000303%-
Discomfort08.01.08.003---
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000606%
Diverticulum07.10.01.001---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.0010.005152%-
Drug hypersensitivity10.01.01.0010.185031%-
Drug ineffective08.06.01.0060.193760%-
Dry eye06.08.02.001--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.0010.004001%
Dyspnoea02.11.05.003; 22.02.01.004--
Dyspnoea at rest02.11.05.004; 22.02.01.025---
Dyspnoea exertional02.11.05.005; 22.02.01.005---
Ear disorder04.03.01.001---
Ear pain04.03.01.0030.000667%
Eczema23.03.04.0060.000970%
Encephalopathy17.13.02.0010.000606%
Enteritis07.08.03.0020.000303%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene